Predictive marker

Results: 31



#Item
1Microsoft Word - 100741workpaper

Microsoft Word - 100741workpaper

Add to Reading List

Source URL: impactaging.com

Language: English
2Microsoft Word - 100741workpaper

Microsoft Word - 100741workpaper

Add to Reading List

Source URL: www.impactaging.com

Language: English
3Trastuzumab (Herceptin) Factsheet This factsheet explains what trastuzumab is, how it works, when it may be given, its benefits and the possible side effects.

Trastuzumab (Herceptin) Factsheet This factsheet explains what trastuzumab is, how it works, when it may be given, its benefits and the possible side effects.

Add to Reading List

Source URL: www2.breastcancercare.org.uk

Language: English - Date: 2015-03-27 11:51:24
4Oncotype DX / Ribbon symbolism / Breast cancer / Trastuzumab / HER2/neu / Adjuvant therapy / Tamoxifen / Metastatic breast cancer / Predictive marker / Medicine / Cancer treatments / Oncology

1342 Consultation Decision Analytical Protocol (DAP) to guide the assessment of gene expression profiling of 21 genes in breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy be

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2015-03-12 00:25:18
5Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
6HER2/neu / Biology / Breast cancer / Pharmaceutical Benefits Scheme / Health / Cancer treatments / Predictive marker / Breast cancer chemotherapy / Medicine / Trastuzumab / Ribbon symbolism

Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
7Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:41
8HER2/neu / Biology / Breast cancer / Pharmaceutical Benefits Scheme / Health / Cancer treatments / Predictive marker / Breast cancer chemotherapy / Medicine / Trastuzumab / Ribbon symbolism

Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
9Microsoft Word - Ratified Short Minutes - MSAC 56th Meeting (2 Aug[removed]doc

Microsoft Word - Ratified Short Minutes - MSAC 56th Meeting (2 Aug[removed]doc

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:42
10Trastuzumab / HER2/neu / Biology / Breast cancer / Management of cancer / Predictive marker / Breast cancer chemotherapy / Ribbon symbolism / Medicine / Cancer treatments

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40